|
|
|
| |
|
|
|
|
|
|
|
|
Make
provision about methods of testing the safety of medicines; and
for |
|
|
|
|
Be
it enacted by the Queen’s most Excellent Majesty,
by and with the advice and |
|
|
consent of the Lords Spiritual
and Temporal, and Commons, in this present |
|
|
Parliament assembled, and
by the authority of the same, as follows:— |
|
|
1 |
Medicines
Safety Evaluation Panel |
|
|
(1) |
The Secretary of State must,
within six months of the date on which this Act is |
|
|
passed, appoint a Medicines
Safety Evaluation Panel (“the Panel”). |
|
|
(2) |
The members of the Panel
are to be appointed by the Secretary of State and |
|
|
must include no fewer than
six members of the National Institute for Health |
|
5 |
|
|
(3) |
The Secretary of State may
nominate one of the members of the Panel to act as |
|
|
|
|
(4) |
The Secretary of State must,
in appointing members to the Panel, take steps to |
|
|
ensure that no members appointed
have any commercial or other interests |
|
10 |
which may conflict with their
duties on the Panel. |
|
|
(5) |
The
Secretary of State may make payments to the chairman of the Panel
by way of |
|
|
remuneration
and make payments to him and other members of the Panel in respect
of |
|
|
expenses
incurred by them in the performance of their duties. |
|
|
(6) |
The Panel shall cease to
exist after it has reported to the Secretary of State under |
|
15 |
|
|
|
|
(1) |
The Panel must conduct a
review of methods of testing the safety of medicines. |
|
|
(2) |
The review must comprise
a comparison of the effectiveness of— |
|
|
(a) |
human biology-based tests,
and |
|
20 |
|
|
| |
|
|
|
|
|
|
|
| |
(3) |
The
medicines to be tested in accordance with section 2(2) must have— |
|
|
(a) |
been licensed for marketing
by the appropriate regulatory authority or |
|
|
have been authorised to enter
clinical trials, |
|
|
(b) |
been withdrawn from sale or
never marketed on grounds of safety, and |
|
|
(c) |
collectively caused a range
of adverse reactions. |
|
5 |
(4) |
The Panel must commission
bodies which it considers appropriate to conduct |
|
|
those human biology-based
tests it regards necessary for the purposes of |
|
|
|
|
(5) |
In determining the types
of test to be conducted for the purposes of subsection |
|
|
(2)(a), the Panel shall have
regard to the desirability of using all available |
|
10 |
|
|
(a) |
computer simulations, |
|
|
(b) |
tests involving human cells,
tissues and DNA, and |
|
|
(c) |
early clinical tests on volunteers.
|
|
|
(6) |
The Panel must send the
Secretary of State a report on its review within two |
|
15 |
years of the date of its
appointment. |
|
|
(7) |
The Secretary of State must
publish the report, save that in doing so he may |
|
|
take such steps as he considers
necessary to protect commercially confidential |
|
|
|
|
|
20 |
“animal-based tests”
means those tests required by Directives 2004/27/ |
|
|
|
|
“early clinical tests”
means tests involving minuscule levels of exposure to |
|
|
|
|
“human biology-based
tests” means tests dependent on human biological |
|
25 |
|
|
3 |
Duty
of Medicines and Healthcare products Regulatory Agency |
|
|
The Medicines and Healthcare
products Regulatory Agency must provide, on |
|
|
request, all information
it holds relating to the testing of products which the |
|
|
Panel requires in pursuance
of its duty to conduct a comparison of tests under |
|
30 |
|
|
|
|
There
shall be paid out of money provided by Parliament any expenses
of the Secretary |
|
|
|
|
|
35 |
(1) |
This Act may be cited as
the Safety of Medicines Act 2011. |
|
|
(2) |
This Act extends to England
and Wales, Scotland and Northern Ireland. |
|
|
| |
|
|
